Context Therapeutics Inc. Common Stock CNTX · Stock Open Context Therapeutics Inc. Common Stock in new tab
Context Therapeutics Inc. Common Stock Analysis (CNTX)
Is Context Therapeutics Inc. Common Stock a good investment? Context Therapeutics Inc. Common Stock (CNTX) is currently trading at 0.6041 USD. Market analysts have a consensus price target of 5.38 USD. This suggests a potential upside from current levels.
Earnings Schedule: Context Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.43.
Investor FAQ
Does Context Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Context Therapeutics Inc. Common Stock?
Context Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -0.42.
Company Profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Community Discussion